«Since several BACE1 inhibitors are currently being evaluated in clinical phase 3 trials for the
treatment of Alzheimer's disease, the identification
of potential
side effects will be
of great importance to ensure a
positive clinical outcome,» said Dr. Jochen Herms, a Professor
of translational brain research at Ludwig - Maximilians - University Munich.